NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB) for ductal carcinoma in situ (DCIS) or Stage I-II primary invasive breast cancer.

This research study aims to gather essential information about the safety and effectiveness of LS301-IT as a potential treatment option for women with early-stage breast cancer. The findings from this study will help determine the drug's suitability for further development and potential use in larger-scale clinical trials. It is a Phase 1b/2, open label and single arm study.

open label: Patients know which treatments are being given to them

single arm: A study where sample of individuals with the targeted medical condition is given the experimental therapy and then followed over time to observe their response.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05900986

Clinical Trial Site: Einstein

To see all available clinical trials click here.